Last reviewed · How we verify
Humibid®
At a glance
| Generic name | Humibid® |
|---|---|
| Also known as | Guaifenesin |
| Sponsor | Reckitt Benckiser LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients (PHASE2)
- A Study to Explore if Long-term Use of Mucinex Can Help With Symptoms in Patients With Stable Chronic Bronchitis. (PHASE4)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Airway Stents for Excessive Dynamic Airway Collapse (NA)
- The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection (NA)
- Mucinex Exploratory Cold Study (PHASE2)
- Mucinex® for Treatment of Filamentary Keratitis (NA)
- Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Humibid® CI brief — competitive landscape report
- Humibid® updates RSS · CI watch RSS
- Reckitt Benckiser LLC portfolio CI